AIM: To investigate the long-term survival and prognostic factors in hepatocellular carcinoma(HCC) patients undergoing radiofrequency ablation(RFA) as a first-line treatment.METHODS: From 2000 to 2013, 316 consecutive...AIM: To investigate the long-term survival and prognostic factors in hepatocellular carcinoma(HCC) patients undergoing radiofrequency ablation(RFA) as a first-line treatment.METHODS: From 2000 to 2013, 316 consecutivepatients with 404 HCC(1.0-5.0 cm; mean: 3.2 ± 1.1 cm) underwent ultrasonography-guided percutaneous RFA as a first-line treatment. There were 250 males and 66 females with an average age of 60.1 ± 10.8 years(24-87 years). Patients were followed for 1 year to > 10 years after RFA(234, 181, 136, and 71 for 3, 5, 7, and 10 years, respectively). Overall local response rates and long-term survival rates were assessed. Survival results were generated using Kaplan-Meier estimates, and multivariate analysis was performed using the Cox regression model. RESULTS: In total, 548 RFA sessions were performed and major complications occurred in 10 sessions(1.8%). Local tumor progression and/or new tumor development were observed in 43.3%(132/305) of the patients during the follow-up period. Overall 5-and 10-year survival rates were 49.7% and 28.4%, respectively. Based on multivariate analysis, three factors were identified as independent prognostic factors for overall survival: Child-Pugh classification(HR = 4.054, P < 0.001), portal vein hypertension(HR = 2.743, P = 0.002), and tumor number(HR = 2.693, P = 0.003). The local progression-free 5- and 10-year survival rates were 42.7% and 19.5%. In addition to the Child-Pugh classification and the number of tumors, the number of RFA sessions(HR = 1.550, P = 0.002) was associated with local progression-free survival.CONCLUSION: RFA can achieve acceptable outcomes for HCC patients as a first-line treatment, especially for patients with Child-Pugh class A, patients with a single tumor and patients without portal vein hypertension.展开更多
Objective To compare the value of contrast-enhanced ultrasound(CEUS)and conventional ultrasound(US)during radiofrequency ablation(RFA)for the treatment of hepatocellular carcinoma(HCC)≥3.0 cm in diameter.Methods A to...Objective To compare the value of contrast-enhanced ultrasound(CEUS)and conventional ultrasound(US)during radiofrequency ablation(RFA)for the treatment of hepatocellular carcinoma(HCC)≥3.0 cm in diameter.Methods A total of 149 HCC patients treated with RFA guided by either CEUS or conventional US between January 2012 and June 2013 were retrospectively analyzed.Patients were divided into different groups based on the type of ultrasound guidance(CEUS or conventional US)and tumor volume(diameter<3.0 or≥3.0 cm).The progressionfree survival(PFS)and complete ablation rates were compared between groups,and risk factors for the PFS were investigated.Results Seventy four patients received CEUS-guided RFA,and conventional US was performed in 75 patients.Among patients with a tumor<3.0 cm,the PFS and complete ablation rates were similar.However,for patients with a tumor≥3.0 cm,those treated with CEUS had a significantly longer PFS(17.3 vs.3.1 months,HR=2.73;95%CI,1.28~5.81;P=0.007)and higher complete ablation rates at 6-and 12-month post-treatment(87.5%vs.57.7%,P=0.042;75.0%vs.38.5%,P=0.009,respectively)than those treated with conventional US-guided RFA.The type of treatment(P=0.024)and maximum tumour size(P=0.011)were both found to be independent factors associated with the PFS.Conclusion Compared with conventional US,CEUS is more effective for guiding RFA in patients with HCC≥3.0 cm.CEUS-guided RFA could target HCC more accurately,and its ability to immediately detect any residual tumor during RFA might contribute to an increase in complete ablation rates and reduced progression.展开更多
Background:To compare the efficacy and safety of surgical resection plus radiofrequency ablation(SR-RFA)with transarterial chemoembolization(TACE)in patients with multifocal hepatocellular carcinoma(HCC)beyond the Mil...Background:To compare the efficacy and safety of surgical resection plus radiofrequency ablation(SR-RFA)with transarterial chemoembolization(TACE)in patients with multifocal hepatocellular carcinoma(HCC)beyond the Milan criteria.Methods:From 2009 to 2015,a total of 469 consecutive patients with multifocal HCC beyond the Milan criteria(≤5 nodules)treated with SR-RFA(n=59)or TACE(n=410)were analyzed.Their overall survival(OS)rate was compared through propensity score matching(PSM)analysis at a ratio of 1:2,and 141 patients were identified(SR-RFA,n=47;TACE,n=94).Subgroup analysis was conducted according to factors associated with treatment options.Results:Before PSM,the 1-,2-and 3-year OS rates were 81.5%,68.3%and 64.3%in the SR-RFA group and 58.7%,35.5%and 24.4%in the TACE group,respectively(all P<0.001).After PSM,the 1-,2-and 3-year OS rates in the SR-RFA group were 81.8%,68.7%and 63.4%,whereas those in the TACE group were 59.3%,36.1%and 19.4%,respectively(all P<0.001).Subgroup analysis also revealed a survival advantage of SR-RFA over TACE in each subgroup.The 30-day mortality rate was 1.22%in the TACE group and nil in the SR-RFA group(P=0.861).Conclusions:SR-RFA provides better a long-term survival rate than TACE for patients with multifocal HCC beyond the Milan criteria.SR-RFA may serve as an alternative treatment for patients with multifocal HCC in a selected patient population.展开更多
目的探讨超声引导下射频消融术(radiofrequency ablation,RFA)联合靶向治疗对晚期肝癌患者生命质量的影响。方法将90例诊断为晚期肝癌的患者随机分为对照组与观察组,每组45例。两组均予吉非替尼联合卡培他滨靶向治疗,观察组在靶向治疗...目的探讨超声引导下射频消融术(radiofrequency ablation,RFA)联合靶向治疗对晚期肝癌患者生命质量的影响。方法将90例诊断为晚期肝癌的患者随机分为对照组与观察组,每组45例。两组均予吉非替尼联合卡培他滨靶向治疗,观察组在靶向治疗的基础上行超声引导经皮腹腔穿刺RFA,治疗前及治疗后4周采用肿瘤生命质量核心量表(core quality of life questionnaire,QLQ-c30)进行评估并比较。结果治疗后两组QLQ-c30整体功能、特异性症状模块各条目评分均明显优于治疗前,观察组上述指标均优于对照组,差异有统计学意义(P<0.05)。结论超声引导下RFA联合靶向治疗较单纯靶向治疗能更好地改善晚期肝癌患者的生命质量。展开更多
基金Supported by the National Natural Science Foundation of ChinaNo.81471768+3 种基金the Natural Science Foundation of Beijing MunicipalityNo.7152031the Beijing Municipal Health System Special Funds of High-Level Medical Personnel ConstructionNo.2013-3-086
文摘AIM: To investigate the long-term survival and prognostic factors in hepatocellular carcinoma(HCC) patients undergoing radiofrequency ablation(RFA) as a first-line treatment.METHODS: From 2000 to 2013, 316 consecutivepatients with 404 HCC(1.0-5.0 cm; mean: 3.2 ± 1.1 cm) underwent ultrasonography-guided percutaneous RFA as a first-line treatment. There were 250 males and 66 females with an average age of 60.1 ± 10.8 years(24-87 years). Patients were followed for 1 year to > 10 years after RFA(234, 181, 136, and 71 for 3, 5, 7, and 10 years, respectively). Overall local response rates and long-term survival rates were assessed. Survival results were generated using Kaplan-Meier estimates, and multivariate analysis was performed using the Cox regression model. RESULTS: In total, 548 RFA sessions were performed and major complications occurred in 10 sessions(1.8%). Local tumor progression and/or new tumor development were observed in 43.3%(132/305) of the patients during the follow-up period. Overall 5-and 10-year survival rates were 49.7% and 28.4%, respectively. Based on multivariate analysis, three factors were identified as independent prognostic factors for overall survival: Child-Pugh classification(HR = 4.054, P < 0.001), portal vein hypertension(HR = 2.743, P = 0.002), and tumor number(HR = 2.693, P = 0.003). The local progression-free 5- and 10-year survival rates were 42.7% and 19.5%. In addition to the Child-Pugh classification and the number of tumors, the number of RFA sessions(HR = 1.550, P = 0.002) was associated with local progression-free survival.CONCLUSION: RFA can achieve acceptable outcomes for HCC patients as a first-line treatment, especially for patients with Child-Pugh class A, patients with a single tumor and patients without portal vein hypertension.
基金the Training Plan for Outstanding Young Teachers of Jilin University(No.419080500356).
文摘Objective To compare the value of contrast-enhanced ultrasound(CEUS)and conventional ultrasound(US)during radiofrequency ablation(RFA)for the treatment of hepatocellular carcinoma(HCC)≥3.0 cm in diameter.Methods A total of 149 HCC patients treated with RFA guided by either CEUS or conventional US between January 2012 and June 2013 were retrospectively analyzed.Patients were divided into different groups based on the type of ultrasound guidance(CEUS or conventional US)and tumor volume(diameter<3.0 or≥3.0 cm).The progressionfree survival(PFS)and complete ablation rates were compared between groups,and risk factors for the PFS were investigated.Results Seventy four patients received CEUS-guided RFA,and conventional US was performed in 75 patients.Among patients with a tumor<3.0 cm,the PFS and complete ablation rates were similar.However,for patients with a tumor≥3.0 cm,those treated with CEUS had a significantly longer PFS(17.3 vs.3.1 months,HR=2.73;95%CI,1.28~5.81;P=0.007)and higher complete ablation rates at 6-and 12-month post-treatment(87.5%vs.57.7%,P=0.042;75.0%vs.38.5%,P=0.009,respectively)than those treated with conventional US-guided RFA.The type of treatment(P=0.024)and maximum tumour size(P=0.011)were both found to be independent factors associated with the PFS.Conclusion Compared with conventional US,CEUS is more effective for guiding RFA in patients with HCC≥3.0 cm.CEUS-guided RFA could target HCC more accurately,and its ability to immediately detect any residual tumor during RFA might contribute to an increase in complete ablation rates and reduced progression.
基金National Natural Science Foundation of China(No.81372650,No.81572296)Zhongshan Science&Technology Innovation Fund(2015).
文摘Background:To compare the efficacy and safety of surgical resection plus radiofrequency ablation(SR-RFA)with transarterial chemoembolization(TACE)in patients with multifocal hepatocellular carcinoma(HCC)beyond the Milan criteria.Methods:From 2009 to 2015,a total of 469 consecutive patients with multifocal HCC beyond the Milan criteria(≤5 nodules)treated with SR-RFA(n=59)or TACE(n=410)were analyzed.Their overall survival(OS)rate was compared through propensity score matching(PSM)analysis at a ratio of 1:2,and 141 patients were identified(SR-RFA,n=47;TACE,n=94).Subgroup analysis was conducted according to factors associated with treatment options.Results:Before PSM,the 1-,2-and 3-year OS rates were 81.5%,68.3%and 64.3%in the SR-RFA group and 58.7%,35.5%and 24.4%in the TACE group,respectively(all P<0.001).After PSM,the 1-,2-and 3-year OS rates in the SR-RFA group were 81.8%,68.7%and 63.4%,whereas those in the TACE group were 59.3%,36.1%and 19.4%,respectively(all P<0.001).Subgroup analysis also revealed a survival advantage of SR-RFA over TACE in each subgroup.The 30-day mortality rate was 1.22%in the TACE group and nil in the SR-RFA group(P=0.861).Conclusions:SR-RFA provides better a long-term survival rate than TACE for patients with multifocal HCC beyond the Milan criteria.SR-RFA may serve as an alternative treatment for patients with multifocal HCC in a selected patient population.
文摘目的探讨超声引导下射频消融术(radiofrequency ablation,RFA)联合靶向治疗对晚期肝癌患者生命质量的影响。方法将90例诊断为晚期肝癌的患者随机分为对照组与观察组,每组45例。两组均予吉非替尼联合卡培他滨靶向治疗,观察组在靶向治疗的基础上行超声引导经皮腹腔穿刺RFA,治疗前及治疗后4周采用肿瘤生命质量核心量表(core quality of life questionnaire,QLQ-c30)进行评估并比较。结果治疗后两组QLQ-c30整体功能、特异性症状模块各条目评分均明显优于治疗前,观察组上述指标均优于对照组,差异有统计学意义(P<0.05)。结论超声引导下RFA联合靶向治疗较单纯靶向治疗能更好地改善晚期肝癌患者的生命质量。